Neutral effect of P2Y12 inhibitors in non-critical COVID-19 hospitalisations Presented ByProf. Jeffrey Berger, New York University Langone, USA TrialACTIV-4A ConferenceAHA 2021 14 January, 2022 16:30
COVID-19: Thromboembolic risk reduction with therapeutic heparin dosing Presented ByProf. Alex Spyropoulos, Northwell Health, USA TrialPhase 3, HEP-COVID ConferenceESC 2021 26 October, 2021 16:34
